Skip to main content

Research News

 

Clinical courses

 

Clinical research courses

  • Study Paves the Way for an Active Agent Against Hepatitis E

    At present, there is no specific active substance against hepatitis E. As the disease kills 70,000 people every year, researchers are actively searching for one. The team from the Department of Molecular and Medical Virology at Ruhr University Bochum, Germany, may have found what they’re looking for.
  • WHO prequalifies new dengue vaccine
    WHO recommends the use of TAK-003 in children aged 6–16 years in settings with high dengue burden and transmission intensity. The vaccine should be administered in a 2-dose schedule with a 3-month interval between doses.
  • Plant Virus Treatment Shows Promise in Fighting Metastatic Cancers in Mice

    An experimental treatment made from a plant virus is effective at protecting against a broad range of metastatic cancers in mice, shows a new study from the University of California San Diego.

  • New Molecule Mimics the Anti-Clotting Action of Blood-Sucking Organisms

    Nature gave ticks, mosquitos and leaches a quick-acting way to keep blood from clotting while they extract their meal from a host.

    Now the key to that method has been harnessed by a team of Duke researchers as a potential anti-clotting agent that could be used as an alternative to heparin during angioplasty, dialysis care, surgeries and other procedures.

  • Pan-cancer analysis uncovers a new class of promising CAR T–cell immunotherapy targets
    While COL11A1 was one of the 156 targets identified that the researchers validated in mouse models, others showed promise in cell lines such as anti-fibronectin CAR T cells. Most targets have yet to be tested but are publicly available for other researchers to pursue.
  • Unraveling the roles of non-coding DNA explains childhood cancer’s resistance to chemotherapy
    Acute lymphoblastic leukemia (ALL) is the most common childhood cancer. Survival rates are over 94% due to modern therapy. However, those with relapsed or recurrent disease, often due to chemotherapy resistance, have a much poorer 30-40% survival rate.
  • Deeper understanding of malaria parasite sexual development unlocks opportunities to block disease spread

    For the first time, the developmental stages of the deadliest human malaria parasite have been mapped in high resolution, allowing researchers to understand this ever-adapting adversary in more detail than previously possible.

  • Scientists Track Doubling in Origin of Cancer Cells

    Working with human breast and lung cells, Johns Hopkins Medicine scientists say they have charted a molecular pathway that can lure cells down a hazardous path of duplicating their genome too many times, a hallmark of cancer cells.

    The findings, published May 3 in Science, reveal what goes wrong when a group of molecules and enzymes trigger and regulate what’s known as the “cell cycle,” the repetitive process of making new cells out of the cells’ genetic material.

  • Researchers Identify Biomarkers in Blood to Predict Liver Cancer
    Early detection has the potential to transform treatment and outcomes in cancer care, especially for cancers like liver cancer, which is typically diagnosed at a late stage with limited options for cure.
  • Tsetse fly protein provides anti-clotting agent with its own on-off switch
    Researchers at the University of Sydney and University of Geneva have developed a new anticoagulant, whose anticlotting action can be rapidly stopped ‘on demand’. The result could lead to new surgical and post-operative drugs that minimise the risk of serious bleeding.
Subscribe to Research News